When endometrial cancer metastasizes, are the mets always the same genetic makeup of the original tumor or is there a possibility of further mutations? In other words, if my original tumor has had genomic testing through an organization like Foundation One, how can I be sure that the mets that have spread to my lungs have the same abnormalities and, therefore, might benefit from an immunotherapy suggested by the genomic testing of the original tumor?